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Abstract Only B lymphocytes can express immunoglobu-
lins according to the traditional immunological theories, and
the expression of immunoglobulin G (IgG) messenger RNA
(mRNA) and protein was found in certain human cancer
cells recently. However, the expression pattern of IgG and
its possible role in human urothelial carcinoma are still
elusive. In this study, we investigated the expression of
IgG in two human urothelial carcinoma cell lines, T24 and
BIU-87, and in 56 cases of clinical urothelial carcinoma
tissues. The mRNA of IgG was positively detected by in
situ hybridization and reverse transcription PCR; further-
more, IgG protein was also positively detected by immuno-
histochemistry and Western blot. Moreover, blockade of
tumor-derived IgG by either antihuman IgG antibody or
antisense oligonucleotides increased cell apoptosis and
inhibited cell growth in bladder cancer cell lines in vitro,
and antihuman IgG antibody could suppress the growth of
xenotransplant tumor in vivo. In addition, either antihuman
IgG antibody or antisense oligonucleotides enhanced the
sensitivity to mitomycin C in bladder cancer cell line T24.
Furthermore, blockade of IgG in bladder cancer cell T24
resulted in upregulation of cleaved caspase-3 and cleaved
poly(ADP-ribose) polymerase. Our results indicated that
bladder cancer cells were capable of expressing IgG, and
blockade of IgG expression induced cell apoptosis through
activation of caspase-dependent pathway. A novel potential
targeted therapy for bladder cancer will be possibly devel-
oped based on these data.
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Immunoglobulins are some certain proteins produced by
plasma cells and lymphocytes and characteristic of these
types of cells. Immunoglobulins play an essential role in
the body’s immune system, and immunoglobulins are com-
posed of four polypeptide chains: two “light” chains (lamb-
da or kappa) and two “heavy” chains (alpha, delta, gamma,
epsilon, or mu). The type of heavy chain determines the
immunoglobulin isotype (IgA, IgD, IgG, IgE, and IgM,
respectively) [1].
However, some recent findings have reported that immu-
noglobulins were found to be expressed in multiple malig-
nant epithelium tumors and activated in hyperplasia
epithelium, but it was negatively expressed in normal epi-
thelial cells [2, 3]. Heavy and light chain constant regions of
immunoglobulin was found in many human epithelial car-
cinoma cell lines, such as MCF-7 (human breast carcinoma
cell line), SW480 (human colon carcinoma cell line), MGC
(human gastric carcinoma cell line), HeLa (human cervical
carcinoma cell line), and HNE2 (human nasopharyngeal
Electronic supplementary material The online version of this article
(doi:10.1007/s13277-013-0717-z) contains supplementary material,
which is available to authorized users.
P.-Y. Liang :H.-Y. Li (*) : Z.-Y. Zhou :Y.-X. Jin : S.-X. Wang :
X.-H. Peng : S.-J. Ou
Department of Urology, The Affiliated Hospital of Medical
College of Hainan, NO.31 Longhua Road, Meilan District,
Haikou 570102 Hainan Province, China
e-mail: haoyli5118@yahoo.com.cn
Tumor Biol. (2013) 34:1783–1791
DOI 10.1007/s13277-013-0717-z
carcinoma cell line) [4]. Furthermore, some human cancer
cell lines could express and secret IgG [5, 6], and IgG and
IgAwere also found to be expressed in oral epithelial tumors
by immunohistochemical analysis [7].
Tumor-derived IgG was found to be involved in the sur-
vival and growth of epithelial tumor cells, and the cancer-
derived IgG stimulated cell growth in an autocrine/paracrine
fashion [8]. This study indicated that tumor-derived IgG con-
tributed to cancer initiation in the precancerous stage when the
epithelial cells were actively proliferating, and selective block-
ade of tumor-derived IgG thusmay initiate a new approach for
cancer therapy and prevention.
However, the expression pattern of IgG in human bladder
cancer has not been investigated. In the present study, we
reported the expression pattern of IgG in urinary bladder
transitional epithelium cancer, and then, we further investi-




For this retrospective study, archival formalin-fixed, paraffin-
embedded tissue specimens from 56 bladder cancer patients,
who underwent radical cystectomy or transurethral resection at
Department of Urology, the affiliated hospital of Hainan
Medical College from July 2005 to June 2006, were recruited.
The 56 patients include 47 men and 9 women, with a mean age
of 60 years (range, 22–86). Meanwhile, the normal control
bladder epitheliums were obtained from 11 cases among those
56 bladder cancer patients, and the normal epitheliums were
taken from the area more than 2.0 cm away from the margin of
cancer tissue. These bladder cancer patients were graded
according to the WHO grading system (G1, 19 cases; G2, 21
cases; G3, 16 cases) and were staged according to the TNM
classification (superficial tumor Tis, Ta, T1: 42 cases; advanced
tumor T2, T3, T4: 14 cases). All procedures were performed
with the approval of the Institutional Review Board.
Cell culture
The human bladder carcinoma cell lines T24 and BIU-87 were
cultured in Dulbecco’s modified eagle’s medium (DMEM, Life
Technologies, Inc.) with 10% fetal calf serum (FCS), 100 U/ml
penicillin, and 100 μg/ml streptomycin. All the cell lines were
grown in a humidified incubator at 37 °C with 5 % CO2.
Immunohistochemistry
Primary antibodies against IgG (IR512, Dako, Denmark)
and CD20 (CD20cy, clone: L26, Dako, Denmark) were used
in this study. Briefly, tissue sections were dewaxed, incu-
bated with hydrogen peroxide for 10 min, incubated in
retrieval buffer solution for antigen recovery, blocked with
normal serum for 10 min, and incubated with a primary
antibody for 60 min, followed by detection using a
Catalyzed Signal Amplification Kit (DAKO, USA); signal
was visualized using diaminobenzidine. Nonimmune goat
or rabbit serum was substituted for the primary antibody
as a negative control. The immunohistochemistry results
were evaluated and classified as − (positive cell under
10 %), + (positive cells 10–30 %), ++ (positive cell under
30–50 %), +++ (positive cells 50–70 %), and ++++ (pos-
itive cells 70–100 %) by one senior pathologist without
knowledge of the clinicopathological outcomes of the
patients.
In situ hybridization
Paraformaldehyde-fixed and paraffin-embedded tissue sec-
tions were deparaffinized, dehydrated, and incubated in
perforating buffer (0.1 M citric acid buffer with 0.5 %
Triton X-100) for 10 min, and then incubated with 3 %
hydrogen peroxide for 20 min. The sections were treated
with proteinase K and hybridized overnight at 37 °C with
the probe against human IgG1 CH1∼CH3 (GenBank ID
AY623427.1). After hybridization, the sections were incu-
bated with antidigoxigenin antibody conjugated with biotin
for 60 min at 37 °C, and then incubated for 50 min with
highly sensitive streptavidin peroxidase (SP) at 37 °C. After
extensive washing, the bound antibody was detected using
DAB for color reaction.
Reverse transcription PCR
Total RNA was extracted from cell lines using TRIzol re-
agent (Invitrogen). After reverse transcription of the total
RNA, the first-strand complementary DNAwas then used as
templates for detection of IgG and β-actin expression. β-
actin was used as internal control. The primers were IgG
(184 bp) (forward, ACT ACA AGA CCA CGC CTC C and
reverse, CGT CGC ACT CAT TTA CCC), β-actin (569 bp)
(forward, ACT ACC TCATGA AGATCC TC and reverse,
CTA AAG ATT GCG TGG CGA GG). PCR products were
electrophoresed on 1.5 % agarose gels containing 0.5 μg/ml
ethidium bromide.
Western blotting analysis
Cells were harvested and lysed with radioimmunoprecipi
tation assay buffer (Upstate, USA). Equal amounts of dena-
tured protein sample were separated by sodium dodecyl sul-
fate polyacrylamide gel electrophoresis and were then
transferred electrophoretically to polyvinylidene fluoride
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membranes (Pall, USA) for immunoblot analysis.
Antibodies used for immunoblot analysis were against
human IgG (IR512, Dako, Denmark), Caspase-3 (1:500
dilution, sc-7272, Santa Cruz, USA), poly(ADP-ribose)
polymerase (PARP) (1:1,000 dilution, sc-1562, Santa
Cruz, USA), GAPDH (1:3,000 dilution, sc-32233, Santa
Cruz, USA). All protein bands were detected using an
enhanced chemiluminescent western blot kit (Cell
Signaling Technology, USA).
Flow cytometry analysis
Cells were collected, washed twice with ice-cold phosphate-
buffered saline (PBS), resuspended in cold PBS, and fixed
with 70 % ethanol. After fixation overnight and subsequent
rehydration in PBS for 30 min at 4 °C, the samples were
stained for 30 min in dark with 50 μg/ml propidium iodide
(Sigma) containing 125 U/ml protease-free RNase, both
diluted in PBS in a FACS flow cytometer(Beckman-
Coulter ELITE, USA).
MTT assay
The logarithmically growing T24 and BIU-87 cells were
seeded in 96-well plate at a density of 2×103 cells/well.
After an overnight growth, cells were treated with goat
antihuman IgG antibody (10 μg/ml; Sigma) or 0.8 μg/ml
concentration of mitomycin C (MMC) alone or in com-
bination. After indicated time duration, 10 μl of 5 mg/ml
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) was added into each well and incubated
for an additional 4 h. Supernatants were removed, and
200 μl of dimethyl sulfoxide was added. After crystals
were dissolved, absorbance at 450 nm was measured in a
microplate reader.
Anti-IgG antibody treatment
Cells were seeded in a 24-well plate at 6×104 cells/ml,
incubated overnight at 37 °C in DMEM with 10 %
FCS. The supernatant was discarded, and goat antihu-
man IgG antibody (25 μg/ml; Sigma) was added to the
culture for additional 48 h incubation. Apoptosis of
cancer cells was assessed by flow cytometry analysis
as described above. Normal nonspecific goat IgG
(25 μg/ml) was used as control. In cell proliferation
assay, cancer cells were seeded in 96-well plate at 2×
103 cells/ml and incubated overnight in DMEM with
10 % FCS. The supernatant was discarded, and the
cancer cells were subsequently treated with goat antihu-
man IgG antibody (10 μg/ml; Sigma) and 0.8 μg/ml
concentration of MMC, alone and combined. Cell pro-
liferation was determined by MTT.
ASODN transfection
The 15-mer phosphoro-thioIate oligodeoxynucleotides were
synthesized by Invitrogen. IgG antisense oligodeoxynucleo
tides (ASODN, 5′-ACA CGG CTG TGT ATT-3′) were com-
plementary to human IgG1 CHI-CH3 mRNA, and the random
nonsense oligodeoxynucleotides (RODN, 5′-CGG GTA TGC
TTCGCC-3′) were used as controls. ASODN and RODNwere
separately transfected into cancer cells using Lipofectamine
2000 (Invitrogen, USA) according to the manufacturer’s in-
structions. Transfected cells were grown at 37 °C for 6 h,
followed by incubation with complete medium for an addition-
al 66 h. When transient transfection was performed for 72 h,
cells were harvested and followed by the further assay.
In vivo Studies
Totally, 25 nude mice (BALB/c) were used for in vivo studies,
and each group had five nude mice. The human bladder
carcinoma cell line T24 cells (5×106) in the logarithmic
growth phase were injected into right armpit of nude mice
(BALB/c). When the tumor became palpable, polyclonal an-
tibody of goat antihuman IgG, which was purified by protein
A-Sepharose 4B column and purchaseed from Chinese acad-
emy of military medical sciences, laboratory of immunology,
Beijing, China, was injected 1.5 mg/tumor intratumorally for
five times with a 3-day interval, along or combined with
intraperitoneal injection of MMC 1.5 mg/kg. The growth of
the tumor was monitored every 3 days. On day 25 after tumor
cell inoculation, the tumors were excised and histologically
Fig. 1 IgG expression in clinical human bladder cancer tissues. a IgG
was strongly expressed in bladder cancer by immunohistochemisty. b
IgG was weakly or negatively expressed in normal bladder transitional
epithelial cells by immunohistochemisty. c CD20 expression was pos-
itive in tumor-infiltrating B lymphocytes, while CD20 protein was
negatively expressed in bladder cancer tissues. d IgG mRNA was
strongly expressed in bladder cancer tissues by in situ hybridization
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examined. Nude mice with T24 xenografts treated with nor-
mal goat IgG, and PBS was used as controls. All procedures
were performed with the approval of the Institutional Review
Board.
Statistical analysis
Data was analyzed using SPSS12.0 software. Data were
expressed as mean ± standard deviation (SD), and t test
was used to determine the significance of differences be-
tween two groups. Differences were considered significant
at p<0.05.
Results
IgG expression in clinical human bladder tumor tissues
For immunostaining study, the positive signal of IgG was
predominantly shown in the cytoplasma of human bladder
tumor cells (Fig. 1a), and negative signal of IgG was found
in normal epitheliums (Fig. 1b). CD20 stainingwas performed
to rule out contamination of infiltrating B cells in cancer
tissues. The tumor-infiltrating B cell was shown as CD20
positive expression, while the CD20 expression in the bladder
cancer cells was negative (Fig. 1c). Furthermore, the mRNA
level of IgG was positively detected in bladder tumor tissues
by in situ hybridization (Fig. 1d).
The expression of IgG was positively detected in
91.1 % (51/56) clinical human bladder tumor tissues by
immunohistochemistry, while the positive IgG expression
was found only in 45.4 % (5/11) normal epitheliums. The
difference of IgG expression was statistically significant
between bladder tumor tissues and normal epitheliums
(p<0.05) (Table 1).
Moreover, the positive expression of IgG was found in
84.2 % (16/19) in grade G1, 90.5 % (19/21) in grade G2
and 100 % (16/16) in grade G3, respectively. However,
the IgG expression was not correlated with tumor grade
and stage (p>0.05).
IgG expression in human bladder cancer cell lines T24
and BIU-87
To completely obviate contamination of infiltrating B cells in
tumor tissues, the expression of IgG was further examined in
two human bladder cancer cell lines T24 and BIU-87 using
four different methods. Immunohistochemistry was
performed to detect IgG expression in two human bladder
cancer cell lines T24 and BIU-87, and positive signal was
found in both of these two cell lines (Fig. 2a, b). The mRNA
Table 1 IgG expression in human urothelial carcinoma tissues and
normal tissues
Group Case Positive degree (n/%)
− + ++ +++ ++++
UC 56 5 (9) 4 (7) 13 (23) 24 (42) 10 (18)
Normal 11 6 (55) 3 (27) 2 (18)
Fig. 2 IgG expression in human bladder cancer cell Lines T24 and
BIU-87. The expression of IgG protein was detected by immunohisto-
chemistry in human bladder cancer cell lines T24 (a) and BIU-87 (b).
The expression of IgG mRNAwas detected by in situ hybridization in
human bladder cancer cell lines T24 (c) and BIU-87 (d). The
expression of IgG mRNA (184 bp products) in human bladder cancer
cell lines T24 and BIU-87 was detected by RT-PCR (e). f Two splitted
subunits of cancer-derived IgG (25 and 50 kDa) was detected by
Western blot in human bladder cancer cell lines T24 and BIU-87.
Human serum IgG was used as positive control
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level of IgG was also found to be positive in T24 and BIU-87
cell lines by in situ hybridization (Fig. 2c, d). Furthermore,
these results were further confirmed by RT-PCR (Fig. 2e) and
Western blot (Fig. 2f).
Effect of blockade of IgG on the proliferation and apoptosis
of bladder cancer cells in vitro
The human bladder cancer cell lines T24 and BIU-87 were
treated with 25 μg/ml concentrations of the goat nonspecific
IgG or anti-IgG antibody, respectively, and the cell growth
was assessed by MTT assay. The inhibition ratio of cell
growth in T24 and BIU-87 treated with goat nonspecific
IgG or anti-IgG antibody were (4.73±3.73)% vs (24.98±
3.81)% and (5.36±1.53)% vs (22.7±3.72)%, respectively.
Hence, anti-IgG antibody could inhibited cell growth in
human bladder cancer cell lines T24 and BIU-87 (p<
0.05). In addition, the inhibitory rate of T24 cells treated
with anti-IgG antibody, MMC, or anti-IgG antibody +
MMC was (25.02±6.71)%, (32.31±6.46)%, and (73.66±
5.81)%, respectively (p<0. 05).
Flow cytometry (FCM) shows the percentages of apopto-
tic cells in T24 cells treated with PBS (Fig. 3a), goat
nonspecific IgG (Fig. 3b), anti-IgG antibody (Fig. 3c),
MMC (Fig. 3d), MMC + nonspecific IgG (Fig. 3e), and
anti-IgG Ab + MMC (Fig. 3f) were 1.1, 2.3, 20.7, 22.4,
28.3, and 53.8 %, respectively. Furthermore, caspase-3 and
PARP were cleaved in T24 cell during the course of apo-
ptosis induced by anti-IgG Ab and MMC (Fig. 3g) by
Western blot. Moreover, the percentages of apoptotic cells
in BIU-87 the goat nonspecific IgG and anti-IgG antibody
were 1.3 vs 15.3 %, respectively (Suppl. Fig 1). These
results indicated that anti-IgG antibody could induced blad-
der cancer cell apoptosis and enhanced MMC-induced cy-
totoxicity in vitro, which was correlated with the activation
of caspase-3 and PARP.
To further investigate the function of cancer derived IgG
in bladder cancer, we transfected a 15-mer S-oligos of
Fig. 3 Antibody against IgG-
induced cell apoptosis in human
bladder cancer cell line T24.
The percentage of apoptosis
cells was tested by FCM after
the treatment with PBS (a),
25 μg/ml goat IgG (b), goat
antihuman IgG (c), MMC (d),
goat IgG + MMC (e), and goat
antihuman IgG + MMC (f) for
72 h. g The caspase-3 and
PARP were assessed by
Western blot in the T24 cells
treated with goat antihuman
IgG and/or MMC
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ASODN into T24 cells to block the expression of IgG. The
inhibitory rate of cell growth in T24 cells treated with
ASODN, MMC, MMC + RODN, and ASODN + MMC
were (21.49±9.20)%, (34.26±6.62)%, (39.22±6.20)%, and
(61.44±5.94)%, respectively (p<0. 05). FCM showed the
percentages of apoptotic cells in T24 cells treated with PBS
(Fig. 4a), RODN (Fig. 4b), 2.5 μΜ ASODN (Fig. 4c), 5 μΜ
ASODN (Fig. 4d), 10 μΜ ASODN (Fig. 4e), MMC
(Fig. 4f), MMC + RODN (Fig. 4g), and MMC + ASODN
(Fig. 4h) were 2.7, 5.2, 13.0, 16.2, 17.7, 22.8, 28.5, and
47.4 %, respectively. Western blot showed caspase-3 and
PARP were cleaved in T24 cell during the course of apo-
ptosis induced by ASODN (Fig. 4i) and indicated that cell
apoptosis was associated with caspase-3 and PARP
activation.
Effect of ASODN against IgG on the proliferation
and apoptosis of bladder cancer cells in vivo
Under the treatment of normal goat IgG, anti-IgG antibody,
MMC, and MMC + anti-IgG antibody, the inhibitory rate of
T24 xenografts in BALB/c nude mice were 2.31, 12.73,
Fig. 4 ASODN against IgG-
induced cell apoptosis in human
bladder cancer cell line T24.
Apoptosis cell percentage of
T24 cell were tested by FCM
after the treatment with PBS
(a), 10 μΜ RODN (b), 2.5 μΜ
ASODN (c), 5.0 μΜ ASODN
(d), 10.0 μΜ ASODN (e),
2.0 μg/ml MMC (f), 10.0 μΜ
RODN+2.0 μg/ml MMC (g),
and 10.0 μΜ ASODN+2.0 μg/
ml MMC (h) for 72 h. g The
caspase-3 and PARP were
assessed by Western blot in T24
cells treated with ASODN for
72 h
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36.81, and 50.51 %, respectively (Fig. 5). Histological ex-
amination demonstrated significant necrosis and apoptosis
in the mice treated with alone MMC or anti-IgG antibody,
while necrosis and apoptosis was seldom shown in control
goat IgG or PBS. In addition, more extensive necrosis and
apoptosis was found in the mice with MMC + anti-IgG
antibody (Fig. 6). These results indicated that anti-IgG anti-
body could induced bladder cancer cell apoptosis and en-
hanced MMC-induced cytotoxicity in vivo.
Discussion
Recently, many publications have shown that human cancer
cell lines could express IgG [5, 6]. In the present study, we
positively detected IgG expression in two human urothelial
carcinoma cell lines T24 and BIU-87 and 56 cases of blad-
der tumor tissues by immunostaining and Western blot.
Because it is possible that IgA and IgG are transferred into
epithelial cells via poly-IgA/G receptor on plasma mem-
brane [9], we further investigated the mRNA level of IgG
expression using in situ hybridization and RT-PCR essen-
tially to rule out this possibility. Taken together, all of these
results indicated that IgG was expressed in human bladder
cancer.
Many studies reported that the growth of tumor grafts could
be enhanced by immune reaction, including antibody produc-
tion [10–12]. Furthermore, several studies found the presence
of circulating IgG reactive with specific tumor-associated an-
tigens and its association with poor prognosis, and demonstrat-
ed the presence of an aberrantly glycosylated IgG population in
cancer patients [13, 14]. Carbohydrate reactive antibodies
might be particularly participating in that the antigen (Ag)
reactive IgGs upon tumor antigen immunization, which
were observed to correlate with tumor growth in experimen-
tal mice models of human melanoma [15]. Such analogical
observations were found in human colon cancer cell later
[16]. Induction of cancer cell apoptosis and inhibition of
cancer growth by blocking tumor-derived IgG, using either
antisense oligodeoxynucleotide (ASODN) or anti-human Ig,
confirmed that IgG secreted by epithelial cancers had some
unidentified capacity to promote the growth and survival of
tumor cells [8]. In order to explore the biological effects of
tumor-derived IgG in human bladder cancer, we blocked the
expression of tumor-derived IgG by either anti-human IgG
antibody or antisense oligonucleotides in vitro. Functional
studies showed that after blockage of IgG in bladder cancer,
the cell growth was inhibited and cell apoptosis was in-
creased. Furthermore, administration of anti-human IgG an-
tibody could suppress the growth of bladder cancer cells in
immunodeficient nude mice xenotransplant tumor. In addi-
tion, combined antihuman IgG antibody or antisense oligo-
nucleotides with mitomycin C could enhance its sensitivity
to mitomycin C in bladder cancer cell T24. These data
indicated that bladder cancer-derived IgG might involved
in the survival and growth of cancer cells.
Fig. 5 Inhibitory effect of goat antihuman IgG and MMC on growth
of human bladder cancer T24 cell xenografts in BALB/c nude mice.
After tumor formation, antihuman IgG was injected intratumorally, and
along or combined with intraperitoneal injection of MMC, once every
3 days in nude mice. The growth of the tumor was monitored every
3 days. On day 25 after treatment, the mice were killed and the tumors
observed histologically (H&E staining)
Fig. 6 The tumor of T24 xenografts were observed histologically in
nude mice. The tumor of T24 xenografts were observed histologically
in nude mice treated with PBS (a), goat non-sepcific IgG (b), goat
antihuman IgG (c), MMC (d), and MMC + goat antihuman IgG (e)
after 25 days treatment (H&E staining, ×400)
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Such antigen-driven antibodies can functionally mimic
growth promoting agents much like siglecs, which are
sialic acid-binding immunoglobulin-like lectins involved
in cell–cell interactions and signalling functions in the
hemopoietic, immune, and nervous systems [17].
However, the biological effects of antibodies cannot be
assessed from their antigen binding properties. Tumor
cells secreting antigenic secreted/shed tumor glycoproteins
can induce a host IgG immune response that can promote
invasion and metastasis by inducing tumor infiltrating
stromal cells to release proinflammatory cytokines and
VEGF [18]. Although the exact mechanism of antibody
enhancement of tumor growth remains unclear, it was
hypothesized that antibodies may do so by blocking target
epitopes on the cancer cells [19]. Further study confirmed
that antibodies may enhance tumor cell proliferation by
immune complex binding and crosslinking of Fc-receptors
expressed either on tumor cells or immune effect cells
augmenting tumor growth and a metastatic phenotype
during transition to malignancy [20]. Human IgG antigen
binding fragment (Fab) in patients with malignancies
might activate ERK-signaling pathways, leading to tumor
cell proliferation and presumably disease progression [21].
In this study, we also investigated the mechanism that
blockade of tumor-derived IgG by either antihuman IgG
antibody or antisense oligonucleotides increased cell apo-
ptosis and inhibited cell growth. Our finding suggested
that antihuman IgG antibody or antisense oligonucleotides
might regulate cell apoptosis through caspase-dependent
pathways.
Although the exact mechanism of IgG expression in
malignant epithelial cells remains unclear, several possible
hypotheses may explain rearranged immunoglobulin vari-
able (VH) region gene transcripts in cancer cells. Either de
novo rearrangement or modification of VH genes in epi-
thelial tumor cells or assimilation of lymphocyte-derived
chromatin should be considered. Constitutive cytidine de-
aminase activation in malignant epithelial cells further
raises a potential for inducing aberrant mutational activity
[22]. Some observations suggested a potential for such
rearrangement and modification. Endothelial cells lying adja-
cent to lymphoma or multiple myeloma cells have revealed
genetic aberrations that are identical to the tumor clone, in-
cluding entire IgH chromosomal translocations. Furthermore,
the genetic aberrations acquired by endothelial cells in these
diseases were maintained following several cycles of cell
culture. Although the underlying mechanisms for acquisition
and maintenance of aberrant genes in endothelial cells are not
clear, several possibilities exist, one of which suggests gene
transfer of apoptotic bodies from tumor cells [23].
Taken together, our data indicate that bladder tumor-derived
IgG may contribute in cancer development. Development of
methods aiming at selective blockade of tumor-derived IgG
thus may constitute a new approach for cancer therapy and
prevention. While the production of IgG by cancer cells de-
rived from epithelium and other proliferating cells has been
established, its function and clinical significance in cancer
development remains to be explored.
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